A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer

Comparison of irinotecan/platinum versus etoposide/platinum chemotherapy for extensive-stage small cell lung cancer: A meta-analysis

(2017) D. Han et al.   EUROPEAN JOURNAL OF CANCER CARE

Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer

(2017) Raheleh Roudi et al.   Cancer Biomarkers

Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trial

(2015) Yuankai Shi et al.   Thoracic Cancer

Prognostic Value of CD44 Variant exon 6 Expression in Non-Small Cell Lung Cancer: a Meta-analysis

(2014) Shuang Zhao et al.   Asian Pacific Journal of Cancer Prevention

Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity

(2013) Elisa Dalla Pozza et al.   BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES

Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors

(2013) Shanthi Ganesh et al.   BIOMATERIALS

Cancer Stem–like Cell Marker CD44 Promotes Bone Metastases by Enhancing Tumorigenicity, Cell Motility, and Hyaluronan Production

(2013) Toru Hiraga et al.   CANCER RESEARCH

CD44 Expression in Intestinal Epithelium and Colorectal Cancer Is Independent of p53 Status

(2013) Jurrit Zeilstra et al.   PLoS One

The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer

(2013) Muhammad Alamgeer et al.   THORAX

Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer

(2012) Tateaki Naito et al.   Journal of Thoracic Oncology

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer

(2011) A. Schmittel et al.   ANNALS OF ONCOLOGY

Hyaluronan-CD44 interactions as potential targets for cancer therapy

(2011) Suniti Misra et al.   FEBS Journal

Small-cell lung cancer

(2011) Jan P van Meerbeeck et al.   LANCET

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease

(2010) P. Zatloukal et al.   ANNALS OF ONCOLOGY

Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial

(2010) Peter Gibbs et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

CD44, a therapeutic target for metastasising tumours

(2010) Véronique Orian-Rousseau   EUROPEAN JOURNAL OF CANCER

Phase II Trial of Irinotecan and Carboplatin for Extensive or Relapsed Small-Cell Lung Cancer

(2009) Gigi Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

(2009) Primo N. Lara et al.   JOURNAL OF CLINICAL ONCOLOGY

A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients

(2008) Peter Gibbs et al.   CHEMOTHERAPY

Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial

(2008) Andreas Hermes et al.   JOURNAL OF CLINICAL ONCOLOGY